The Monjuvi therapy. Targeted lymphoma drug from MorphoSys

Monjuvi comes as a ready-to-use vial, targeting relapsed diffuse large B-cell lymphoma with a CD19-directed antibody therapy. Anyone holding MorphoSys AG stock (ISIN DE0006632003) should know this product.

Monjuvi lands in the nurse’s gloved hand as a cool glass vial, the clear solution catching the fluorescent light before it is spiked into an IV bag. In that short moment, the lymphoma therapy by MorphoSys feels very real for patients and the team around Dr. Jean-Paul Kress.

What Monjuvi is used for

Monjuvi is a CD19-directed monoclonal antibody used together with lenalidomide to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. It is a targeted therapy, designed to bind CD19 on B cells and help the immune system attack malignant cells. In the United States, the drug is marketed under the brand name Monjuvi, while in the European Union it is known as Minjuvi.

Diffuse large B-cell lymphoma, or DLBCL, is the most common type of non-Hodgkin lymphoma and often behaves aggressively. For patients whose disease has returned or never responded after prior lines of therapy, options have been limited, especially if they are older or medically unfit for high-dose chemotherapy and stem cell transplant. Monjuvi slots into this gap as an off-the-shelf antibody with a defined dosing schedule that does not require the logistics of cell collection and manufacturing seen with CAR-T therapies.

Dosing and administration in practice

According to the Monjuvi prescribing information, the recommended dose is 12 mg per kilogram of body weight, given intravenously in combination with lenalidomide. The dosing schedule starts with infusions on days 1, 4, 8 and 11 of cycle 1, followed by weekly dosing in cycles 2 and 3 and then every two weeks from cycle 4 onwards. Each treatment cycle is 28 days, and therapy may continue until disease progression or unacceptable toxicity, so some patients stay on the drug for many months.

In the infusion unit, that translates into repeated visits, blood draws and vital checks. Nurses prepare Monjuvi vials in a laminar airflow hood, diluting the clear solution into saline, while pharmacists double-check dosing based on the patient’s weight. Dr. Kress and his medical team explain potential infusion reactions, such as fever, chills or shortness of breath, and ensure premedication is given as recommended to reduce these risks. Patients often report the smell of disinfectant and the hum of infusion pumps as their defining sensory backdrop during this therapy.

Clinical data and safety profile

Monjuvi received accelerated approval in the United States based on the phase 2 L-MIND study, which evaluated tafasitamab, the antibody component in Monjuvi, in combination with lenalidomide in adult patients with relapsed or refractory DLBCL who were ineligible for autologous stem cell transplant. In this single-arm study, the overall response rate was reported at around 55 percent, including a complete response rate of approximately 24 percent, with median duration of response extending beyond one year in many patients. These numbers are important in a setting where historical response rates with conventional chemotherapy have been considerably lower.

Safety data from L-MIND and the prescribing information show that the most common adverse reactions include neutropenia, anemia, thrombocytopenia, infusion-related reactions, fatigue and diarrhea. Serious infections such as pneumonia can occur, and patients on the combination therapy require regular blood counts and clinical monitoring. Oncologists like Dr. Kress weigh these risks against the potential for durable responses, often using tools such as the International Prognostic Index to discuss expected outcomes with patients. Many patients describe fatigue as a persistent physical sensation during treatment, alongside emotional uncertainty.

Pricing, reimbursement and market positioning

Monjuvi is a hospital-only product, supplied as a concentrate for solution for infusion in vials that contain 200 mg of tafasitamab. Pricing is not prominently disclosed by MorphoSys, but analyst reports and U.S. pharmacy databases suggest list prices per vial in the low five-digit dollar range, depending on contracting and discounts. Given the weight-based dosing, the total drug cost for a full course of therapy can reach several hundred thousand dollars for a typical adult patient.

In practice, U.S. patients often access Monjuvi through commercial insurance, Medicare or Medicaid, with MorphoSys and its partner offering patient assistance programs for those who are underinsured. In the European Union, where the product is branded Minjuvi, pricing and reimbursement discussions are conducted country by country, often involving health technology assessment bodies that scrutinize the clinical data and cost-effectiveness. This positioning as a high-cost specialty oncology therapy places Monjuvi in direct comparison with CAR-T products and other novel agents, even though its mechanism and logistics differ.

Competition and combination strategies

The relapsed or refractory DLBCL market has become crowded, with therapies such as CAR-T cell products, antibody-drug conjugates and small-molecule inhibitors competing for patient segments. Monjuvi’s CD19-directed mechanism overlaps with some of these approaches, creating questions around sequencing and cross-resistance that researchers are actively exploring. MorphoSys highlights the convenience of an off-the-shelf infusion therapy that does not require the manufacturing timelines associated with autologous cellular products.

Beyond its approved indication, tafasitamab has been studied in combination with other agents, including checkpoint inhibitors, in earlier research settings. MorphoSys regularly updates its pipeline chart to show ongoing trials and life-cycle management strategies around the antibody backbone. The company’s scientists describe the process of optimizing infusion regimens and exploring biomarkers as a balance between laboratory data, clinical experience and what patients can realistically tolerate across repeated cycles. For now, the approved label remains focused on adult relapsed or refractory DLBCL patients ineligible for autologous stem cell transplant.

Context and MorphoSys stock

For retail investors, Monjuvi represents a key commercial asset for MorphoSys, particularly in the United States market where sales numbers are closely watched in quarterly reports. Analysts from major banks and specialist biotech research houses regularly compare Monjuvi revenue trends with other oncology products in similar lines of therapy, noting that uptake depends on physician familiarity, clinical guidelines and competition from cell therapies. The MorphoSys AG share (ISIN DE0006632003), listed in Germany, reflects expectations for this product’s performance alongside the wider pipeline, but investors need to weigh regulatory, clinical and competitive risks carefully.

Key facts about Monjuvi

• Product: Monjuvi (tafasitamab-cxix)
• Manufacturer: MorphoSys AG
• Category: Accessory/Spare part (oncology medication)
• Market launch: Initial U.S. approval in 2020 for relapsed or refractory DLBCL ineligible for autologous stem cell transplant.
• MSRP / Price: Hospital-only specialty oncology drug; list prices per vial reported in the low five-digit U.S. dollar range, subject to contracts and discounts.
• Availability: Available by prescription in the United States as Monjuvi; available in the European Union under the brand Minjuvi, subject to local reimbursement.
• Target group: Adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.
• Highlight / USP: CD19-directed monoclonal antibody therapy delivered as off-the-shelf intravenous infusions, used in combination with lenalidomide in a defined dosing schedule.